Equities
Health CareMedical Equipment and Services
  • Price (USD)75.09
  • Today's Change-0.06 / -0.08%
  • Shares traded1.62m
  • 1 Year change+16.47%
  • Beta0.7319
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

  • Revenue in USD (TTM)4.13bn
  • Net income in USD543.80m
  • Incorporated1990
  • Employees7.07k
  • Location
    Hologic Inc250 Campus DriveMARLBOROUGH 01752United StatesUSA
  • Phone+1 (302) 658-7581
  • Fax+1 (302) 655-5049
  • Websitehttps://www.hologic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Baxter International Inc11.02bn-355.00m11.45bn38.00k--1.5818.091.04-0.6925-0.665421.4614.090.46183.146.08290,078.90-1.48-0.8441-1.87-1.0335.0538.63-3.20-2.031.183.420.5684--2.66-1.31-293.68---8.521.60
Revvity Inc2.86bn239.88m11.46bn11.00k48.811.5817.764.012.072.0824.4963.950.23263.464.15--1.953.232.133.5854.7758.488.4013.581.405.230.30758.523.67-5.47-15.26-19.91-1.050.00
Globus Medical Inc2.77bn423.78m11.81bn5.30k28.522.7016.874.263.093.0920.0932.680.54411.294.59522,604.508.324.709.535.1865.3466.4015.309.732.4715.960.00020.0060.6226.25-16.19-7.8810.29--
Penumbra Inc1.33bn164.03m13.27bn4.50k81.629.7573.149.954.144.1433.6334.700.82761.077.42296,399.6010.181.4211.311.5866.8063.2112.301.964.18--0.01710.0012.8616.89-84.59-21.98-0.853--
Guardant Health Inc902.57m-398.79m13.86bn2.00k------15.36-3.21-3.217.27-2.840.64114.028.85451,510.30-28.33-24.20-33.49-26.8363.7663.23-44.18-91.243.12-10.701.47--31.0428.088.98--10.58--
Solventum Corp8.40bn1.52bn14.13bn22.00k9.372.836.911.688.698.6948.0128.750.58513.857.91381,909.1010.61--13.32--54.18--18.13--1.141.760.5075--0.6954---64.41------
Align Technology Inc4.03bn410.35m14.17bn20.95k34.903.5034.563.515.665.6655.5856.430.64835.333.85--6.598.119.6711.9768.2570.4010.1712.311.24------0.89910.30-2.61-25.40----
Cooper Companies Inc4.09bn374.90m16.28bn15.00k44.321.9721.633.981.871.8720.4642.060.33121.715.29272,826.703.038.043.328.8665.5466.019.1624.661.136.320.23320.20495.0610.98-4.449.483.15--
Hologic Inc4.13bn543.80m16.76bn7.07k31.163.1919.974.062.412.4118.2823.510.46082.576.79583,663.406.0711.226.8212.8556.5160.2013.1821.993.3215.760.32460.001.741.66-28.35-12.69-0.5168--
Insulet Corp2.52bn246.20m17.65bn3.90k72.7812.7552.887.003.453.4534.8519.680.8331.626.02646,641.008.136.0010.057.0371.4667.059.769.222.1827.390.4230.0022.0722.92102.76104.84-4.75--
West Pharmaceutical Services Inc3.02bn491.70m17.71bn10.60k36.475.8027.495.876.756.7541.4142.440.77574.635.13284,707.6012.3215.6114.4618.7035.5838.0015.8818.842.18--0.063810.20-1.929.48-16.9715.3124.435.84
Illumina Inc4.34bn850.00m17.78bn8.97k21.306.5324.704.095.465.4627.8417.820.67092.615.41--13.13-10.1517.32-12.1566.6165.3919.57-23.181.72--0.4221---0.66336.04169.505.32----
Zimmer Biomet Holdings Inc8.23bn705.00m18.95bn17.00k26.961.4910.532.303.553.5541.4264.110.37031.105.17--3.173.033.583.4669.7171.018.569.101.104.740.371829.107.206.08-21.98--9.260.00
Steris PLC5.83bn708.66m23.88bn17.79k33.883.3419.954.107.197.1859.0972.930.56584.926.12327,662.406.915.047.595.5144.1143.7512.2110.691.7520.990.209437.516.2412.4910.648.4011.528.99
Data as of Feb 11 2026. Currency figures normalised to Hologic Inc's reporting currency: US Dollar USD

Institutional shareholders

45.05%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202523.89m10.71%
T. Rowe Price Investment Management, Inc.as of 30 Sep 202521.55m9.66%
BlackRock Fund Advisorsas of 30 Sep 202512.44m5.58%
Manulife Investment Management (US) LLCas of 30 Sep 202510.45m4.69%
SSgA Funds Management, Inc.as of 30 Sep 20259.98m4.47%
Geode Capital Management LLCas of 30 Sep 20255.90m2.64%
Victory Capital Management, Inc. (Investment Management)as of 30 Sep 20255.47m2.45%
Invesco Advisers, Inc.as of 30 Sep 20253.95m1.77%
Black Creek Investment Management, Inc.as of 30 Sep 20253.74m1.68%
Invesco Capital Management LLCas of 30 Sep 20253.12m1.40%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.